News and Press Releases

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...

Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024

Regent’s Place 338 Euston Road London NW1 3BG

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

5 November 2024 –Tokyo, Japan and London and Cardiff, UK – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio...

Category: BioManufacturing
Posted: November 6, 2024

Midtown East 9-7-2 Akasaka Minato-ku Tokyo 107-0052

DRUG DISCOVERY 2024: CONNECTING MINDS, TRANSFORMING SCIENCE, EMPOWERING COMMUNITY

We are proud to be media partners of ELRIG's Drug Discovery 2024! Europe’s largest conference for the drug discovery community returns to London, with scientific tracks covering not only therapeutic...

Category: Drug Discovery
Posted: August 29, 2024

ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK

Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing

Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing 23 July 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO...

Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 23, 2024

Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Evotec and Pfizer collaborate to advance drug discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases 11 July 2024, Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:...

Category: Drug Discovery
Posted: July 11, 2024

Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US

Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: June 12, 2024

Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK

Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery

Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...

Category: Drug Discovery
Posted: June 10, 2024

Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK

GSK’s Omjjara▼ (momelotinib) is accepted for use within NHS Scotland, in line with its licence, for eligible adult myelofibrosis patients with moderate to severe anaemia

Clinicians in Scotland will now have the option to use momelotinib for the treatment of disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia Momelotinib is...

Category: Other, Pharmaceutical
Posted: June 10, 2024

980 Great West Rd, London TW8 9GS

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Exploring advanced technologies to help bring novel therapies to patients faster Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, predictive design of manufacturing processes and...

Category: Biotechnology, Drug Discovery
Posted: May 16, 2024

Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany

Pharma and Regulatory Giants Tackle AI Trust and Legislative Challenges at Largest Ever Pistoia Alliance Annual Conference

Survey of life sciences experts found 70% recognise potential for AI, but many are struggling to get started or implement it at scale due to challenges including data integrity and...

Category: Clinical Trials, Logistics
Posted: May 8, 2024

401 Edgewater Pl, Wakefield, Massachusetts, US

How the Birmingham Drug Discovery Hub created an investment-ready ‘drug library’

18 April 2024 -- Birmingham, UK -- A novel approach to drug discovery is enabling University of Birmingham, UK, researchers to overcome the ‘valley of death’, where projects fail due...

Category: Drug Discovery
Posted: April 18, 2024

Edgbaston Birmingham, B15 2TT

GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting

Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...

Category: Pharmaceutical
Posted: April 8, 2024

X‑Chem Adds Chief Technology Officer to Bolster Its Digital Drug Discovery Strategy 

2 April 2024 -- Massachusetts, US -- X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr Erin Davis as chief technology officer....

Category: Drug Discovery
Posted: April 2, 2024

100 Beaver Street Waltham, MA 02453

Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery

Expansion to SemaCyte Microcarrier platform enables optical barcoding and pooling of adherent cells to augment drug discovery high-content imaging and other screening processes Access available through Semarion’s Early Adopter Programme....

Category: Drug Discovery
Posted: March 20, 2024

Cavendish Laboratories JJ Thomson Ave Cambridge CB3 0HE UK

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics 11 March 2024 -- Dundee, UK --...

Category: Drug Discovery
Posted: March 11, 2024

University Incubator Dundee Technopole James Lindsay Place Dundee DD1 5JJ Scotland, UK